Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trading Halts

Loxo Oncology (LOXO) PT Lowered to $108 at Citi on Bayer Collaboration for Laro & LOXO-195; 'Deal Not Exactly What We Expected, But Still Very Good'November 15, 2017 6:54 AM Loxo Oncology (LOXO) to Resume Trading at 7:30 AM ETNovember 14, 2017 7:20 AM Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195November 14, 2017 7:00 AM Loxo Oncology (LOXO) Halted, News PendingNovember 14, 2017 6:55 AM